Sunshine Biopharma’s (SBFM) Sell (E+) Rating Reaffirmed at Weiss Ratings

Sunshine Biopharma (NASDAQ:SBFM)‘s stock had its “sell (e+)” rating reiterated by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Sunshine Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sunshine Biopharma presently has an average rating of “Hold” and a consensus target price of $7.00.

Sunshine Biopharma Price Performance

NASDAQ:SBFM opened at $1.68 on Wednesday. The business’s 50-day moving average is $1.47 and its two-hundred day moving average is $1.50. Sunshine Biopharma has a 12 month low of $1.17 and a 12 month high of $3.90. The firm has a market capitalization of $7.65 million, a PE ratio of -0.01 and a beta of 1.48.

Sunshine Biopharma (NASDAQ:SBFM) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.28). Sunshine Biopharma had a negative net margin of 17.35% and a negative return on equity of 26.04%. The company had revenue of $9.41 million during the quarter, compared to analysts’ expectations of $12.10 million.

Institutional Trading of Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Altium Capital Management LLC bought a new position in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,466 shares of the company’s stock, valued at approximately $96,000. Sunshine Biopharma comprises approximately 0.2% of Altium Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Altium Capital Management LLC owned 1.86% of Sunshine Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 41.98% of the stock is currently owned by hedge funds and other institutional investors.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.